You're listening to Plenary Session.

In this episode of Plenary Session, I'm going to talk about a few things, two of which I was dragged into.

One, post-publication metrics of randomized clinical trials with and without null findings.

This is a research letter that appeared in JMA.

I'm going to take you through it.

Next, I'm going to talk about a paper that appeared in JAMA Network Open.

JAMA No.

Association of Primary Care Clinic appointment time with clinician ordering and patient completion

of breast and colorectal cancer screening.

This is a paper that's gotten a lot of publicity,

including a provocative headline in the New York Times that says, don't see your doctor in the

afternoon. Finally, I'm going to talk about a wonderful paper by Alex Drillin and colleagues that was

featured on the Twitter feed of Greg Riley. It's a great story, and I really enjoyed

this paper. It's called exceptional responders with invasive mucinous adenocarcinomas, a phase

two trial of Bortesim have been patients with KRAS G12D mutant lung cancers. This is a unique

story because the authors here did something that a lot of other people wouldn't do, which is

they decided to take a hypothesis and put it to

the test. They deserve a lot of credit here, and they have gone above and beyond the call of duty,

and in doing so, they have set the standard for what many others should do. You won't want to miss

this discussion. But first, I'm going to start with a little correction that was raised to my

attention by an astute listener.

And finally, I have an interview with no other than Christopher Booth.

...